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What is Evidence Based Medicine?
Since the 1990s, the concept of ‘evidence based medicine’ (EBM) has received growing
interest. Its main rationale was the recognition that systematic synthesis of evidence from
high quality clinical research should be guiding clinical practice. Important developments in
EBM included the introduction of structured abstracts and of systematic reviews.1 Nowadays,
EBM can be described as ‘healthcare practice that is based on integrating knowledge gained
from the best available research evidence, clinical expertise, and patients’ values and
circumstances’.2 While results from randomised controlled trials (RCTs), and especially the
systematic review of several RCTs, are often considered as ‘best evidence’, RCTs are not
suitable for all types of clinical questions, such as assessing the accuracy of diagnostic tests or
the impact of prognostic factors. Evidence based medicine should therefore not be limited to
RCTs and meta-analyses. Its main goal is to guide clinical decision making that is based on
the best available evidence.2,3
Whether EBM has made a difference in the past decade was discussed in a special theme
issue of the British Medical Journal (October 30, 2004). EBM has made a difference in
contributing to the discussion and development of systematically collecting and summarising
evidence of clinical research. EBM has not only created enthusiasm, but has also received
criticism. For example, critics opposed the idea that EBM would restrict choices in terms of
promoting a single ‘right’ way to practice, would declare RCTs as the only type of study to be
useful, or would be driven by costs and cost savings.2 One of the big challenges for EBM in
the coming years will be to implement clinical evidence into clinical practice. EBM should
not only produce best available evidence, but should also find effective ways for
implementation and to make this evidence accessible to clinicians, consumers, policy makers,
and other stakeholders.2,4,5
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Evidence from Clinical and Epidemiological Studies in Leprosy
Publication of clinical studies in leprosy dates back to the early 1950s when dapsone was
introduced for the treatment of leprosy, and immune-suppressant drugs for the management
of leprosy reactions were examined. Over the years much research has been conducted in the
field of leprosy, gradually contributing to our knowledge base. Many clinical studies
however, were small-scale and often did not fulfil the rigorous methodological criteria that we
have become accustomed to in clinical practice over the past two decades.
Among the first larger multicentre randomised controlled trials (RCTs) were the THELEP
trials (1977–1983), which examined five multidrug regimens in 215 untreated multibacillary
leprosy (MB) patients. The results gave strong support to the intermittent, rifampicin-
containing regimen (MDT) recommended by the WHO Study Group on Chemotherapy for
Leprosy Control for the treatment MB leprosy.6 Clinical trials were also undertaken to
establish the value of a single-dose combination of rifampicin, ofloxacin and monocycline
(ROM) to treat paucibacillary leprosy.7 The follow-up of these trials has unfortunately been
poor. Recently, an international open trial was started of a uniform multi-drug therapy
regimen for 6 months for all types of leprosy patients.8
In the late 1980s and 1990s large prospective cohort studies were conducted, such as
the ALERT MDT Field Evaluation Study (AMFES),9 – 12 and the Bangladesh Acute Nerve
Damage Study (BANDS).13 – 15 These studies were instrumental in describing the incidence
of nerve function impairment (NFI) and in identifying risk factors and prognostic factors for
nerve damage. An important off-shoot of BANDS was the development of a clinical
prediction rule for NFI in leprosy patients.16,17 The abundant data from these studies were
used to develop three multicentre RCTs in prevention of disability in leprosy (TRIPOD).18 – 20
The trials, which started in 1998, examined the effects of prophylactic corticosteroids in
preventing NFI, and of corticosteroids for treating mild and long-standing NFI. In 1999 a new
study was designed because of remaining questions regarding underlying mechanisms of
neuropathy, treatment of acute and recurrent nerve damage and reactions, and early diagnosis
of nerve damage. This was the International Nerve Function Impairment and Reaction
(INFIR) study, a prospective multicentre cohort study investigating prediction, detection and
pathogenesis of peripheral neuropathy and reactions in leprosy.21 – 23
After studies of chemoprophylaxis with dapsone in the 1970s in India,24 and in the 1990s
with ROM in Micronesia,25 a large RCT on chemoprophylaxis (a single dose of rifampicin)
for contacts of leprosy patients was initiated in 2002 in Bangladesh, the study on contact
transmission and chemoprophylaxis in leprosy (COLEP).26,27 The results of this study are
expected to be the basis for possible recommendations regarding the implementation of
chemoprophylactic strategies in leprosy control in future.
Evidence from Systematic Reviews in Leprosy
We performed three Cochrane reviews to systematically evaluate the best available
information and evidence for interventions to treat nerve damage and reactions in leprosy.
Two reviews assessed the effects of corticosteroids and decompressive surgery for treating
nerve damage in leprosy, respectively.28,29 In this issue of Leprosy Review a shortened
Cochrane review on the role of corticosteroids in treating nerve damage is published. The
third Cochrane review, which is in progress, examines the effects of interventions to treat
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ENL.30 Recently another Cochrane review has also been published on interventions for skin
changes caused by nerve damage in leprosy.31
While Cochrane reviews focus on evidence from RCTs, we anticipated that only a few
RCTs had been conducted in the area of treating nerve damage and its consequences. Indeed,
there were only three trials available involving 513 people on corticosteroids and two trials
involving 88 people on decompressive surgery. None of the trial results could be combined in
a meta-analysis and we could not draw any robust conclusions about the effectiveness of
these interventions for treating nerve damage in leprosy, especially on the longer-term. The
Cochrane review on interventions for skin changes assessed the effects of self-care, dressings
and footwear in preventing and healing secondary damage to the skin in persons affected by
leprosy. In this review eight trials with a total of 557 participants were included and it was
concluded that there is a lack of high quality research in the field of ulcer prevention and
treatment in leprosy.31 In all Cochrane reviews the results of non-randomised studies were
discussed, since they may confirm evidence from RCTs or provide ‘second best’ available
evidence, especially if the studies were properly designed and conducted.
Evidence Based Medicine in Leprosy Practice
Evidence from research has certainly led to better practice in leprosy control. The
introduction of MDT has been a great step forward in reducing the number of people with
leprosy, and identification of risk factors and prognostic factors of NFI has led to improved
diagnosis and monitoring of patients. But sometimes it is unclear whether practice has been
guided by best evidence or any evidence from research at all, as illustrated by the
recommendations with respect to MDT treatment, especially for MB patients. In 1981, the
WHO recommended a minimum of 2 years treatment for MB patients, which was shortened
to 24 months in 1994 and later further shortened to the currently recommended 12 months.32
Relapse rates are acceptably low with the 24-month treatment.33 There is no evidence
however, to support the shortened duration of treatment to 12 months for MB patients. On the
contrary, published data show an increased risk of relapse in the long-term for patients with
high bacterial loads.34 – 35 Changes in guidelines or recommendations should be based on
evidence from well-conducted research to maintain effective leprosy control.36,37 Recently,
the ILEP published a report with evidence-based graded recommendations on different
aspects of leprosy control, diagnosis and treatment.38
Conclusion
While the importance and value of evidence based medicine (EBM) and of well-designed
RCTs have been acknowledged within the leprosy research and medical community, some
may still misunderstand the concept of EBM or worry about the ‘superiority’ of RCTs or
systematic reviews compared to non-randomised studies or clinical experience. But EBM is
not restricted to RCTs because many clinical questions cannot or need not be answered by a
RCT (e.g. accuracy of diagnostic tests, the power of prognostic factors). And when evidence
of RCTs is lacking, one should identify and assess the next best available evidence. We can
conclude that evidence based practice in leprosy has improved in recent years and that the
concept of EBM is becoming more accepted and established. On the other hand, there is still
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much need for improvement in conducting clinical research in leprosy. Evidence from good
research is essential for good clinical practice, but it should guide, not dictate, clinical
practice. Evidence based medicine must lead to practice where the best available research
evidence, clinical experience and patient’s values go hand in hand to achieve the best care and
cure for individual patients.
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